Pleural effusion.
Pleural disease remains a commonly encountered clinical problem for both general physicians and chest specialists. This review focuses on the investigation of undiagnosed pleural effusions and the management of malignant and parapneumonic effusions. New developments in this area are also discussed at the end of the review. It aims to be evidence based together with some practical suggestions for practising clinicians.
Medford
A R
AR
Southmead Hospital, Acute Lung Unit, Southmead Hospital, Bristol, UK.
Medford
A
A
Maskell
N
N
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy / Q000379:methods; D002408:Catheters, Indwelling; D015505:Chest Tubes; D003952:Diagnostic Imaging / Q000379:methods; D004322:Drainage; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D058851:GPI-Linked Proteins; D006801:Humans; D008562:Membrane Glycoproteins / Q000627:therapeutic use; D000090204:Mesothelin; D010996:Pleural Effusion / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D016211:Transforming Growth Factor alpha / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005343:Fibrinolytic Agents; D058851:GPI-Linked Proteins; D008562:Membrane Glycoproteins; D016211:Transforming Growth Factor alpha; D042461:Vascular Endothelial Growth Factor A; D000090204:Mesothelin